$23.8 M

PSTV Mkt cap, 23-Sept-2021
Plus Therapeutics Net income (Q1, 2021)-2.7 M
Plus Therapeutics EBIT (Q1, 2021)-2.5 M
Plus Therapeutics Cash, 31-Mar-202114.4 M
Plus Therapeutics EV15.9 M
Get notified regarding key financial metrics and revenue changes at Plus TherapeuticsLearn more
Banner background

Plus Therapeutics Income Statement

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

6.4m3.7m7.0m

Revenue growth, %

(43%)91%

Cost of goods sold

1.3m1.1m

Gross profit

5.1m2.5m

Gross profit Margin, %

79%69%

Sales and marketing expense

3.6m2.0m468.0k

R&D expense

11.7m8.6m5.4m2.7m

General and administrative expense

7.6m6.3m4.8m6.4m

Operating expense total

24.6m17.0m10.7m9.1m

EBIT

(20.7m)(12.7m)(3.7m)(9.6m)

EBIT margin, %

(323%)(346%)(52%)

Interest expense

2.0m1.9m1.9m

Interest income

33.0k43.0k55.0k50.0k

Pre tax profit

(8.2m)

Income tax expense

Net Income

(22.7m)(12.6m)(10.9m)(8.2m)

EPS

(0.8)(1.7)(8.3)

Plus Therapeutics Balance Sheet

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

9.6m5.3m17.6m8.3m

Accounts Receivable

145.0k286.0k1.2m

Inventories

3.2m2.9m107.0k

Current Assets

14.9m9.6m19.8m9.2m

PP&E

3.1m2.6m2.2m1.8m

Goodwill

3.9m3.9m372.0k372.0k

Total Assets

31.6m24.0m23.2m12.1m

Accounts Payable

4.8m3.4m3.3m789.0k

Short-term debt

13.6m14.2m11.2m6.5m

Current Liabilities

18.4m17.6m14.5m8.5m

Long-term debt

646.0k528.0k

Total Debt

13.6m14.2m11.9m7.0m

Total Liabilities

18.6m18.8m22.1m9.1m

Common Stock

58.0k15.0k4.0k7.0k

Additional Paid-in Capital

413.3m418.4m426.4m436.5m

Retained Earnings

(401.7m)(414.4m)(425.3m)(433.5m)

Total Equity

13.0m5.2m1.2m3.0m

Debt to Equity Ratio

1 x2.7 x10.2 x

Debt to Assets Ratio

0.4 x0.6 x0.5 x

Financial Leverage

2.4 x4.6 x20 x4 x

Plus Therapeutics Cash Flow

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(22.7m)(12.6m)(10.9m)(8.2m)

Depreciation and Amortization

2.2m2.0m896.0k366.0k

Accounts Receivable

1.1m(173.0k)(1.2m)1.2m

Inventories

251.0k475.0k259.0k

Accounts Payable

(1.8m)(1.5m)(28.0k)(1.2m)

Cash From Operating Activities

(18.1m)(12.0m)(5.9m)(8.4m)

Purchases of PP&E

(295.0k)(133.0k)(67.0k)

Cash From Investing Activities

(1.7m)(133.0k)5.6m(493.0k)

Long-term Borrowings

(4.7m)(3.8m)(5.4m)

Cash From Financing Activities

16.8m7.2m12.6m(319.0k)

Net Change in Cash

(3.0m)(4.9m)12.3m(9.2m)

Interest Paid

1.4m1.3m1.2m567.0k

Plus Therapeutics Ratios

USDFY, 2017

Revenue/Employee

173.3k

Debt/Equity

1 x

Debt/Assets

0.4 x

Financial Leverage

2.4 x

Plus Therapeutics Employee Rating

2.919 votes
Culture & Values
3.4
Work/Life Balance
3.1
Senior Management
2.4
Salary & Benefits
2.8
Career Opportunities
2.9
Source